Continuous Subcutaneous Insulin Infusion (CSII) pump therapy improves blood glucose control and lifestyle flexibility as compared to multiple-daily insulin injections. Yet less than half of people with type 1 diabetes currently use a pump and fewer use a companion continuous glucose monitoring (CGM) sensor. More convenient, reliable systems are needed to realize the promise of an artificial pancreas that reduces the daily burden of diabetes.
People on CSII pump therapy change their infusion set every third day, over one hundred times per year. Capillary’s novel set is designed to reduce the burden of managing diabetes by:
First-generation Artificial Pancreas System integrating Insulin Pump and Continuous Glucose Monitor
CSII catheter with multiple holes infusing insulin across many tissue layers
Capillary Biomedical, Inc. is developing an infusion set that doesn’t kink when inserted and that works reliably day-to-day. Multiple holes distribute insulin to a larger volume of subcutaneous tissue than traditional sets. Reliable access to more capillary blood and lymph vessels results in more consistent absorption with a more predictable effect on blood glucose levels.
CAUTION – Investigational device. Limited by United States law to investigational use.